International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 2 , Pages 319-326 , 1 February 2001

Therapeutic targets in radiotherapy

Presented at ICTR 2000, Lugano, Switzerland, March 5–8, 2000.

  • J.Martin Brown, Ph.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Dr. J. Martin Brown, Division Radiation Biology, Department of Radiation Oncology, Stanford University School of Medicine, CCSR South, Room 1255, Stanford, CA 94305-5152

,Accepted 31 August 2000.

References 

  1. McKenna WG, Weiss MC, Bakanauskas VJ, et al.  The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys. 1990;18:849–859
  2. Miller AC, Kariko K, Myers CE, et al.  Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer. 1993;53:302–307
  3. Alapetite C, Baroche C, Remvikos Y, et al.  Studies on the influence of the presence of an activated ras oncogene on the in vitro radiosensitivity of human mammary epithelial cells. Int J Radiat Oncol Biol Phys. 1991;59:385–396
  4. Bos JL. Ras oncogenes in human cancer (A review). Cancer Res. 1989;49:4682–4689
  5. Kohl NE, Mosser SD, deSolms SJ, et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 1993;260:1934–1937
  6. James GL, Goldstein JL, Brown MS, et al.  Benzodiazepine peptidomimetics (Potent inhibitors of Ras farnesylation in animal cells). Science. 1993;260:1937–1942
  7. Prendergast GC, Davide JP, deSolms SJ, et al.  Farnesyltransferase inhibition causes morphologic reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 1994;14:4193–4202
  8. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors (Focus on Rho). Oncogene. 1998;17:1439–1445
  9. Bernhard EJ, Kao G, Cox AD, et al.  The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 1996;56:1727–1730
  10. Bernhard EJ, McKenna WG, Hamilton AD, et al.  Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 1998;58:1754–1761
  11. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem. 1995;270:6221–6226
  12. Cohen-Jonathan E, Muschel RJ, McKenna WG, et al.  Farnesyltransferase inhibitors potentiate the anti-tumor effect of radiation on a human tumor xenograft expressing activated H-ras. Radiat Res. 2000;154:125–132
  13. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203–212
  14. Hale RJ, Buckley CH, Gullick WJ, et al.  Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol. 1993;46:149–153
  15. Grandis JR, Melhem MF, Gooding WE, et al.  Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–832
  16. Baselga J, Norton L, Masui H, et al.  Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993;85:1327–1333
  17. Fan Z, Baselga J, Masui H, et al.  Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53:4637–4642
  18. Akimoto T, Hunter NR, Buchmiller L, et al.  Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5:2884–2890
  19. Wollman R, Yahalom J, Maxy R, et al.  Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 1994;30:91–98
  20. Maciejewski B, Withers HR, Taylor JM, et al.  Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx (tumor dose—response and repopulation). Int J Radiat Oncol Biol Phys. 1989;16:831–843
  21. Dent P, Reardon DB, Park JS, et al.  Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 1999;10:2493–2506
  22. Gill GN, Kawamoto T, Cochet C, et al.  Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem. 1984;259:7755–7760
  23. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997;3:2703–2707
  24. Naramura M, Gillies SD, Mendelsohn J, et al.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother. 1993;37:343–349
  25. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935–1940
  26. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy (biology, rationale and preliminary clinical results). Invest New Drugs. 1999;17:259–269
  27. Rubin Grandis J, Chakraborty A, Melhem MF, et al.  Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene. 1997;15:409–416
  28. Ezekiel MP, Robert RF, Meredith RF, et al.  Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation on patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol. 1998;17:A1522
  29. Vaupel P, Schlenger K, Knoop C, et al.  Oxygenation of human tumors (evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements). Cancer Res. 1991;51:3316–3322
  30. Brizel DM, Sibley GS, Prosnitz LR, et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–289
  31. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumor oxygenation status by a polarographic needle electrode. Acta Oncol. 1994;33:383–389
  32. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat Res. 1997;147:541–550
  33. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother and Oncol. 1996;41:31–40
  34. Brizel DM, Dodge RK, Clough RW, et al.  Oxygenation of head and neck cancer (changes during radiotherapy and impact on treatment outcome). Radiother Oncol. 1999;53:113–117
  35. Fyles AW, Milosevic M, Wong R, et al.  Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48:149–156
  36. Knocke TH, Weitmann HD, Feldmann HJ, et al.  Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999;53:99–104
  37. Hockel M, Schlenger K, Aral B, et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509–4515
  38. Graeber TG, Osmanian C, Jacks T, et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996;379:88–91
  39. Sundfor K, Lyng H, Rofstad EK. Tumor hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer. 1998;78:822–827
  40. Brizel DM, Scully SP, Harrelson JM, et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–943
  41. Brown JM, Siim BG. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol. 1996;6:22–36
  42. Wang J, Biedermann KA, Brown JM. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 1992;52:4473–4477
  43. Lloyd RV, Duling DR, Rumyantseva GV, et al.  Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol. 1991;40:440–445
  44. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990;50:7745–7749
  45. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 1993;53:4633–4636
  46. Peters LJ, Rischin D, Hicks RJ, et al.  Extraordinary tumor control in Phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer. (Abstr.) Int J Radiat Oncol Biol Phys. 1999;45:148–149
  47. Patterson LH. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents (A new class of bioreductive agent). Cancer Metastasis Rev. 1993;12:119–134
  48. McKeown SR, Hejmadi MV, McIntyre IA, et al.  AQ4N (An alkylaminoanthraquinone N-oxides showing bioreductive potential and positive interaction with radiation in vivo). Br J Cancer. 1995;72:76–81
  49. von Pawel J, von Roemeling R, Gatzemeier U, et al.  Tirapazamine plus cisplatin vs. cisplatin in advanced nonsmall-cell lung cancer (A report of the international CATAPULT I study group). J Clin Oncol. 2000;18:1351–1359
  50. Huang SM, Harari PM. Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas (Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis). Clin Cancer Res. 2000;6:2166–2174

☆ This work was supported by grant CA 15201 from the National Cancer Institute, DHHS.

PII: S0360-3016(00)01482-6

International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 2 , Pages 319-326 , 1 February 2001

Article Tools

* Image Usage & Resolution